Large language models (LLMs) have shown considerable promise in clinical decision support. However, existing approaches often rely on multi-step reasoning or multi-agent collaboration to execute clinical guidelines, introducing substantial computational overhead without reliably preventing decision errors. To address these limitations, we propose a framework for Medical Decision Execution (MedDEx) that integrates structured patient states with deterministic rule execution to support guideline-based treatment planning. MedDEx separates clinical record interpretation from guideline execution, leveraging LLMs to extract patient information and generate treatment plans while assigning guideline-defined decision logic to a rule executor. Experiments across multiple clinical guideline benchmarks demonstrate that MedDEx improves decision accuracy while reducing inference costs. Further analyses highlight the critical roles of structured patient representations and deterministic rule execution, suggesting that additional LLM reasoning does not necessarily translate into better guideline adherence.
Figures & tables
Figure 1: The importance of guideline execution and the division of responsibilities. Top: Deterministic rule execution is more reliable than LLM-based guideline execution given matched inputs. Bottom: MedDEx improves decision performance by refining routing inputs and allocating responsibilities for TNM computation.
Figure 2: Overview of MedDEx. Top: LLM-executed agents assign scenario selection to the model. Middle: MedDEx assigns record interpretation and plan generation to the LLM, and TNM computation and scenario routing to rules. Bottom (dashed): coding assistants draft rule packs, audits and tests guide revision, and the authors review the code before evaluation. The graph is simplified.
Qwen3-8B
Llama-3.1-8B-Instruct
MedGUIDE
MEGA-CDP
MedGUIDE
MEGA-CDP
Method
Acc.
Concl.
Path OT
Acc.
Concl.
Path OT
Single LLM
68.77
83.17
77.60
66.65
74.31
71.70
Guideline-RAG
51.68
76.00
76.95
54.78
67.41
72.89
MedAgents ( Tang et al., 2024 )
69.36
77.15
73.72
56.09
67.34
64.92
MDAgents ( Kim et al., 2024 )
66.03
78.64
72.84
50.29
65.38
69.00
Table 1: LLM execution vs. rule execution of the same guideline. MedGUIDE reports option accuracy (%); MEGA-CDP reports conclusion agreement (%) and path similarity (%). Best in bold, second underlined; the shaded row is ours. ⋆ : Rules execute the guideline.
TNM Staging
Treatment Recommendation
End-to-End Decision Support
Acc(%) ↑
RQ ↑
Precision(%) ↑
F1 ↑
Precision(%) ↑
F1 ↑
Method
ZH
EN
ZH
EN
ZH
EN
ZH
EN
ZH
EN
ZH
EN
Base model: Qwen2.5-7B-Instruct
Direct prompting
0.10
2.20
33.24
36.56
38.19
57.05
41.38
52.86
40.98
55.51
39.80
45.48
Guideline-RAG
2.70
2.60
39.77
38.91
36.77
48.32
43.88
49.90
40.03
48.64
42.60
46.28
MedAgents ( Tang et al., 2024 )
5.40
6.30
46.04
51.28
44.09
55.99
51.38
51.42
40.58
45.76
47.70
49.16
Table 2: Results on LungCURE. Staging, treatment planning with the reference stage, and the end-to-end task from the record, in Chinese (ZH) and English (EN). F1 is the LungCURE plan agreement score and RQ the staging reasoning score. Best in bold, second underlined; shaded rows are ours. ⋆ : rules execute the guideline.
Figure 3: Downstream effects of the execution boundary. Qwen2.5-7B, English. (a) Agreement with reference T, N, and M categories and exact TNM. (b) LungCURE plan agreement by reference stage group. (c) End-to-end plan agreement against measured model tokens per case. Scores measure benchmark agreement; the cost protocol is in Appendix A.2 .
TNM
Treatment
End-to-end
Variant
Acc ↑
P ↑
F1 ↑
P ↑
F1 ↑
MedDEx (full)
26.90
73.90
65.50
70.58
57.62
w/o rule selection
26.90 0.0
65.17 − 8.7 ∗
60.81 − 4.7 ∗
64.15 − 6.4 ∗
54.39 − 3.2 ∗
w/o stage calculator
8.08 − 18.8 ∗
73.90 0.0
65.50 0.0
70.69 +0.1
56.32 − 1.3 ∗
w all nine guidelines
26.90 0.0
60.27 − 13.6 ∗
49.82 − 15.7 ∗
61.24 − 9.3 ∗
44.89 − 12.7 ∗
Table 3: Ablation results of MedDEx. Values below each score indicate changes from the full model. ∗ denotes a 95% bootstrap confidence interval excluding zero.
Plan agreement
Stage
Routing input
Exact
Group
consistency
MedDEx (full)
67.0
78.9
71.6
− stage calculator
65.3
77.9
68.5
− staging call
54.5
65.5
54.3
− typed state
24.7
59.6
46.4
Table 4: Effect of routing inputs on rule execution. Results on Qwen2.5-7B, English (%). The rule executor remains unchanged while input components are progressively removed. Plan agreement is measured against scenarios extracted from clinician plans. Stage consistency is evaluated against reference TNM categories.
Stage computed by
Patient state
the model
the rules
free text
46.2 ∗
48.9 ∗
structured
55.9 ∗
57.6
Table 5: Effect of patient state representation and staging responsibility. End-to-end plan agreement (F1) on Qwen2.5-7B, English. The rule router remains unchanged across all settings. ∗ indicates a 95% bootstrap confidence interval excluding zero relative to the full system.
MedGUIDE
MEGA-CDP
Method
Calls
Sec
Calls
Sec
Single LLM
1.0
0.9
1.0
49.7
Guideline-RAG
1.0
2.3
1.0
8.0
MedAgents
20.7
152.3
20.5
211.1
MDAgents
19.4
303.9
17.1
399.3
MA-RAG
1.1
1.5
5.9
164.9
Table 6: Computational cost per case across clinical guideline benchmarks. Results on Qwen3-8B using the same GPU and concurrency settings. We report the average number of model calls and execution time (seconds) per case. Best in bold, second underlined. ⋆ indicates rule-based guideline execution.
All
Non-met.
Metastatic
Scenario chosen by
Exact
Grp.
Exact
Exact
scenario list only (§ 5.1 , Q1)
38.3
54.4
69.4
4.9
+ guideline entry rules, verbatim
59.5
75.2
69.2
49.1
+ chain of thought
58.3
94.2
64.2
52.1
+ 9 worked examples
35.4
93.3
58.2
11.0
+ self-consistency, 5 samples
36.1
93.3
58.2
12.5
Table 7: Improving LLM-based scenario routing does not close the gap. All methods receive identical patient states and reference stages. We report overall scenario agreement and exact agreement across non-metastatic and metastatic cases (%).
Appendix figures & tables6 assets
Supplementary material from the paper’s appendix.
Appendix
Dataset
Guideline
Size
Task
MedGUIDE
53 author trees
7,747
multiple-choice decision
MEGA-CDP
440 guideline trees
7,458
decision path and conclusion
LungCURE
9 NCCN/CSCO scenarios
1,000
staging, plan, end to end
Appendix
Table 8: Guideline benchmarks. LungCURE cases are available in Chinese and English.
Scenario
Entry condition (checked in order)
Adv. driver + , later line
M1, driver + , prior therapy and progression
Adv. driver + , first line
M1, driver +
Oligometastatic
M1, oligometastatic, ≤ 5 lesions, first line
Adv. driver − , later line
M1, prior therapy and progression
Adv. driver − , first line
M1
Postoperative adjuvant
M0, curative resection done
Appendix
Table 9: Guideline scenarios and the rules that select them.
Treatment (T2)
End-to-end (T3)
Method
Calls
In
Out
s
Calls
In
Out
s
Guideline-RAG
1.0
2.9
0.59
0.8
1.0
2.9
0.70
0.8
DermAgent
4.6
12.0
1.80
2.3
4.6
12.1
1.82
2.1
LCAgent ⋆
1.8
3.5
0.47
2.4
7.8
22.3
4.18
4.5
MedAgents
9.1
19.2
3.95
4.9
9.0
19.0
4.23
5.2
MDAgents
10.7
27.8
7.35
8.8
10.7
28.0
7.63
9.1
Appendix
Table 10: Cost per case. All methods use the same model, hardware, and concurrency. Calls, input and output tokens (thousands), and average time cover the full pipeline. ⋆ : rules execute the guideline.
Accuracy (%)
Stage
Expl.
T ↑
N ↑
M ↑
TNM ↑
RQ ↑
Calculator
Rule (ours)
52.49
70.79
67.43
26.90
70.78
Calculator
Model’s reply
52.49
70.79
67.43
26.90
46.49
Model
Model’s reply
27.05
36.47
44.15
8.08
44.60
Appendix
Table 11: Staging and its explanation. The stage comes from the stage calculator or the model’s own answer; the explanation comes from the rule that set each category or the model’s own answer. RQ is the judge’s reasoning score for T, N, and M. Best in bold, second underlined; the shaded row is the full system.
Treatment (Task 2)
End-to-end (Task 3)
Method
P ↑
R ↑
F1 ↑
#drugs
P ↑
R ↑
F1 ↑
#drugs
Direct prompting
48.8
38.1
39.7
3.8
47.3
43.0
42.3
4.3
Guideline-RAG
42.2
40.1
38.2
3.9
42.2
41.8
39.0
4.1
MedAgents
49.1
36.4
38.3
3.6
41.1
44.7
38.9
5.6
MDAgents
46.9
35.6
36.8
3.5
44.1
38.8
37.6
4.1
MA-RAG
52.2
39.4
41.2
3.5
52.2
38.8
41.1
3.5
Appendix
Table 12: Drug metrics without an LLM. We compare the drug names in each plan with the clinician’s plan and report precision, recall, F1, and drugs per plan; no language model is used for scoring. Best in bold, second underlined; shaded rows are ours. ⋆ : rules execute the guideline.
Record: 1.8 cm lung adenocarcinoma, already resected by lobectomy; 1 of 2 hilar nodes positive ; EGFR L858R mutation.
Clinician: stage T1bN1M0 → postoperative adjuvant therapy → osimertinib for ≥ 3 years.
Table 13: Case study. Each row shows how a system read the patient and the plan it wrote; key facts in the record are in blue. ✓ : matches the clinician; ∼ : partly matches, with a staging error; ✗ : differs from the reference setting. MedDEx records the key facts, computes the reference stage, and selects postoperative adjuvant treatment.